Brief profiles of these recently formed companies: CaveoMed, Checkmate, Metacrine, and Thrive Bioscience.
[CaveoMed GMBH]
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
